Related references
Note: Only part of the references are listed.Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Anna Marie Mulligan et al.
CLINICAL CANCER RESEARCH (2013)
Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells
Tong Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Protective Role of the Inflammatory CCR2/CCL2 Chemokine Pathway through Recruitment of Type 1 Cytotoxic γδ T Lymphocytes to Tumor Beds
Telma Lanca et al.
JOURNAL OF IMMUNOLOGY (2013)
NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells
Ravikumar Muthuswamy et al.
CANCER RESEARCH (2012)
RAE-1ε Ligand Expressed on Pancreatic Islets Recruits NKG2D Receptor-Expressing Cytotoxic T Cells Independent of T Cell Receptor Recognition
Mary A. Markiewicz et al.
IMMUNITY (2012)
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Stephen R. Mattarollo et al.
CANCER RESEARCH (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
被撤回的出版物: Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs (Retracted article. See vol. 17, pg. 826, 2010)
S. D. Reed et al.
CANCER GENE THERAPY (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D
Cai Zhang et al.
HUMAN IMMUNOLOGY (2008)
Cancer immunosurveillance: NKG2D breaks cover
Hans-Gustaf Ljunggren
IMMUNITY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
Mechanisms involved in synergistic anticancer immunity of Anti-4-1BB and Anti-CD4 therapy
Beom K. Choi et al.
CANCER RESEARCH (2007)
Doxorubicin directs the accumulation of interleukin-12-induced IFNγ into tumors for enhancing STAT1-dependent antitumor effect
Shiguo Zhu et al.
CLINICAL CANCER RESEARCH (2007)
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46
Thierry Walzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Natural killer cells as an initial defense against pathogens
Melissa B. Lodoen et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
Andrew Ewens et al.
CANCER RESEARCH (2006)
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
K Hiraoka et al.
BRITISH JOURNAL OF CANCER (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Selective infiltration of CCR5+CXCR3+ T lymphocytes in human colorectal carcinoma
H Musha et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
NKG2D function protects the host from tumor initiation
MJ Smyth et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Roles of the NKG2D immunoreceptor and its ligands
DH Raulet
NATURE REVIEWS IMMUNOLOGY (2003)
Interleukin-12 and the regulation of innate resistance and adaptive immunity
G Trinchieri
NATURE REVIEWS IMMUNOLOGY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation
S Gilfillan et al.
NATURE IMMUNOLOGY (2002)
The role of the NKG2D immunoreceptor in immune cell activation and natural killing
AM Jamieson et al.
IMMUNITY (2002)
Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
E Vivier et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array
S Li et al.
GENE THERAPY (2002)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site
S Li et al.
GENE THERAPY (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages
A Diefenbach et al.
NATURE IMMUNOLOGY (2000)